Treating Arterial Stiffness in Metabolic Syndrome and Type 2 Diabetes Mellitus
Niki Katsiki1, Eugenia Gkaliagkousi1, Asterios Karagiannis1, Dimitri P. Mikhailidis2, *
Identifiers and Pagination:Year: 2013
First Page: 102
Last Page: 106
Publisher Id: TOHYPERJ-5-102
Article History:Received Date: 25/10/2013
Revision Received Date: 26/10/2013
Acceptance Date: 26/10/2013
Electronic publication date: 13/12/2013
Collection year: 2013
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Arterial stiffening characterizes ageing and several diseases related to increased cardiovascular (CV) risk such as the metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), hypertension, obesity and smoking. Several studies have shown that arterial stiffness is a strong, independent predictor of CV morbidity and mortality risk in such patient populations. Lifestyle measures and drugs frequently prescribed in MetS and T2DM patients such as hypolipidaemic, antihypertensive, hypoglycaemic and antiplatelet agents, may improve arterial stiffness, thus further reducing vascular risk. The current review considers the effects of these drugs and lifestyle changes on arterial stiffness in MetS and T2DM patients. The potential clinical implications of such effects on treatment decisions in clinical practice remain to be established. Multifactorial interventions may be even more beneficial in terms of CV risk reduction and thus their impact on arterial stiffness should also be evaluated.